Preliminary data show that treatment with patiromer is well tolerated and results in clinically meaningful decreases in serum potassium.
In a study of hemodialysis patients, the more hyperkalemia excursions, the higher the risk for short-term mortality.
KDQOL and EuroQol-5D-3L responses show worse quality of life among kidney disease patients who develop hyperkalemia.
In a study, nearly 17% of patients with mild hyperkalemia progressed to moderate to severe hyperkalemia during the 2 years following the date of their first mild hyperkalemia event.
Patients with CKD who discontinued ACE inhibitors or angiotensin receptor blockers after a hyperkalemia episode had a 2.6-fold increased risk of all-cause mortality compared with patients who continued taking the drugs.
Hyperkalemia in patients with chronic kidney disease (CKD) stage 3 or 4 more than doubles their risk of progressing to CKD stage 5, a study found.
In a study of patients with advanced chronic kidney disease and resistant hypertension, a significantly higher proportion of patients taking patiromer vs placebo remained on spironolactone after 12 weeks.
In a study of patients on peritoneal dialysis, hyperkalemia was associated with increased risks of all-cause and arrhythmia-related mortality in non-Hispanic blacks and whites, but was not associated with either outcome in Hispanics.
In a study, hospitalized heart failure patients who reduced their dose of mineralocorticoid antagonists due to hyperkalemia had worse survival.
This real world study examined maximum-dose patiromer in patients with end-stage renal disease and severe hyperkalemia in the emergency department, but the drug’s onset of action remains unclear.